Cabergoline in the Treatment of Parkinson’s Disease

  • Takashi TsuboiEmail author
  • Hirohisa Watanabe
  • Masahisa Katsuno
  • Gen SobueEmail author
Living reference work entry


Cabergoline, an ergot dopamine agonist with a long elimination half-life, has been proved to be effective for treating Parkinson’s disease (PD) either as monotherapy in de novo patients or as an adjunct to levodopa therapy in patients with advanced PD. Typically, cabergoline is the second choice when patients do not respond adequately to other antiparkinsonian drugs. In the United States, cabergoline is recommended for the treatment of hyperprolactinemic disorders, either idiopathic or because of pituitary adenomas. Clinicians should be aware of the risk of fibrosis, especially of the heart valves. Perhaps, the underlying mechanism for the development of fibrosis is associated with the activation of serotonin receptor subtype 5-HT2B. A meta-analysis reported that the risk of valvular regurgitation increased by 7.25 times in patients with PD taking cabergoline. Additionally, the mean cumulative dose of cabergoline was positively related to the odds ratio concerning valve regurgitation, although the possibility of developing valvular regurgitation is not excluded even with low dose of cabergoline. Thus, regular screening with echocardiography is imperative for the early detection of valvular dysfunction. Furthermore, chest X-rays, urine tests, and blood tests, including erythrocyte sedimentation rate and/or C-reactive protein, should be performed regularly. Currently, the recommended dose of cabergoline is up to 3 mg once daily.


  1. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli MG, Cocchiara G, Dostert P. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica. 1993;23:1377–89.CrossRefGoogle Scholar
  2. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18:733–46.CrossRefGoogle Scholar
  3. De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz. 2013;38:868–80.CrossRefGoogle Scholar
  4. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A, et al. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord. 2007;22:1550–5.CrossRefGoogle Scholar
  5. Högl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson’s disease. Neuropsychopharmacology. 2003;28:1866–70.CrossRefGoogle Scholar
  6. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology. 1996;46:1062–5.CrossRefGoogle Scholar
  7. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology. 1996;47:785–8.CrossRefGoogle Scholar
  8. Japanese Society of Neurology. Treatment guidelines for Parkinson’s disease 2011 [Internet]. 2011.
  9. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71:474–80.CrossRefGoogle Scholar
  10. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.CrossRefGoogle Scholar
  11. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33:147–61.CrossRefGoogle Scholar
  12. Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065–78.CrossRefGoogle Scholar
  13. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson’s disease treated with levodopa. Drugs. 1998;55(Suppl 1):17–22.CrossRefGoogle Scholar
  14. National Institute for Health and Care Excellence. Parkinson’s disease in adults [Internet]. 2017.
  15. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280–6.CrossRefGoogle Scholar
  16. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 1997;48:363–8.CrossRefGoogle Scholar
  17. Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A, et al. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study. J Neural Transm. 2006;113:1909–13.CrossRefGoogle Scholar
  18. Stowe R, Ives N, Clarke CE, Deane K, Hilten V, Wheatley K, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7):CD007166.Google Scholar
  19. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol. 1996;243(1):68–72CrossRefGoogle Scholar
  20. Ulm G, Schuler P. Cabergoline versus pergolide: a video-blinded, randomised multicenter cross-over study. Aktuelle Neurol. 1999;26:360–5.CrossRefGoogle Scholar
  21. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, et al. Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol. 2002;161:2209–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of NeurologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Brain and Mind Research CenterNagoya UniversityNagoyaJapan

Section editors and affiliations

  • Toshiharu Nagatsu
    • 1
    • 2
  • Akira Nakashima
    • 3
  1. 1.Fujita Health University School of MedicineToyoakeJapan
  2. 2.Institute of Environmental MedicineNagoya UniversityNagoyaJapan
  3. 3.Department of Physiological ChemistryFujita Health University School of MedicineToyoake, AichiJapan

Personalised recommendations